Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system
Date receipt dossier: 
2 jan 1996
Pharmaceutical study code: 
GLIB 201-E-00
Company / Sponsor: 
Sandoz Pharma, LTD
Phase: 
II
Indication category: 
Cancer therapy
Disease: 
Newly diagnosed or recurrent Glioblastoma multiforme
Therapeutic approach: 
Suicide gene/ pro drug
Genetic modification: 
Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)
Method of transfer of nucleic acid of interest: 
Amphotropic Murine Leukemia Virus
Administered biological material: 
Retroviral vector producing cells (PA 317)
Route of administration: 
Intratumoral
Locations in Belgium: 
Hôpital Erasme, Brussels
Type of procedure: 
Contained use only
Current status: 
Authorized